首页/数据集/Identification of epigenetically silenced RYR2 by DNA methylation profiling in head and neck cancer squamous cell carcinoma

Identification of epigenetically silenced RYR2 by DNA methylation profiling in head and neck cancer squamous cell carcinoma

ChEBI2021-06-11 更新2026-07-12 收录

癌症表观遗传学

头颈癌生物标志物

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-MTAB-7468 数据链接链接失效反馈

官方服务：

资源简介：

Identification of epigenetically silenced RYR2 by DNA methylation profiling in head and neck cancer squamous cell carcinoma

应用场景：

创建时间：

2021-06-11

癌症表观遗传学

甲基化测序

We performed UPLC-MS/MS to investigate global 5mC and 5hmC levels in sixteen pairs of HCC and non-HCC samples and two HCC cell lines (97L and LM6 cells). We found that 5mC and 5hmC were frequently dec

Figshare2016-01-19 更新70

Epigenomic study identifies a novel mesenchyme homeobox2-GLI1 transcription axis involved in cancer drug resistance, overall survival and therapy prognosis in lung cancer patients

癌症表观遗传学

药物耐药性

Several homeobox-related gene (HOX) transcription factors such as mesenchyme HOX-2 (MEOX2) have previously been associated with cancer drug resistance, malignant progression and/or clinical prognostic

DataONE2020-06-24 更新60

Mapping Context-Aware Phosphosite Regulation of Protein–Protein Interactions Using Deep Learning and Pan-Cancer Proteomics

磷酸化位点调控蛋白互作预测

癌症表观遗传学

Phosphorylation dynamically orchestrates the protein–protein interaction (PPI) network that governs cellular signaling, and its dysregulation frequently drives malignant transformation and neurodegene

NIAID Data Ecosystem30

Additional file 4 of Association of expression of epigenetic molecular factors with DNA methylation and sensitivity to chemotherapeutic agents in cancer cell lines

癌症表观遗传学

肿瘤化疗敏感性预测

Additional file 4: Table S4. Significant strong trans- and cis-correlations of GMD expression with methylation of individual probes in the pancancer dataset satisfying p 0.5.

Figshare2021-03-06 更新60

Gene expression profile in relapsed or metastatic HNSCC patients treated with cetuximab and platinum therapy

头颈癌生物标志物

基因表达与治疗响应

First line chemotherapy with platinum and cetuximab is usually offered to RM-HNSCC pts. In the Extreme trial a median progression free survival (PFS) time of 5.6 months was reported. However, a small

NIAID Data Ecosystem30

Identification of epigenetically silenced RYR2 by DNA methylation profiling in head and neck cancer squamous cell carcinoma

资源简介：

相关数据集